Saturn V Capital Management LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Saturn V Capital Management LP reported 17 stock positions worth $456.0 million. Its top holding was Abivax SA-ADR (ABVX) at 14.9% of the portfolio, followed by Amylyx Pharmaceuticals (AMLX, 13.7%) and Jazz Pharmaceuticals (JAZZ, 8.7%). Compared with Q2 2025, it opened 2 new positions, sold out of 9, added to 8 and reduced 7. The biggest buy was Abivax SA-ADR (ABVX, shares +29%) and the biggest sale an exit from Moonlake Immunotherapeutics (MLTX).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $456.0M (Q3 2025)
- SEC Filing
- 0001964437-25-000013 ↗ filed Nov 14, 2025
Holdings Value
Holdings 17 stocks · $456.0M
| ABVX Abivax SA-ADR | 14.92% | 801,224 | $68.0M | Add +28.7% |
| AMLX Amylyx Pharmaceuticals Inc. | 13.72% | 4,604,878 | $62.6M | Add +41.2% |
| JAZZ Jazz Pharmaceuticals PLC | 8.69% | 300,610 | $39.6M | Add +45.3% |
| DYN Dyne Therapeutics Inc. | 7.42% | 2,674,469 | $33.8M | Add +83.8% |
| COGT Cogent Biosciences Inc. | 6.38% | 2,025,041 | $29.1M | Reduce -11.9% |
| PCVX Vaxcyte Inc. | 6.23% | 788,441 | $28.4M | Add +44.9% |
| CELC Celcuity Inc. | 5.13% | 473,828 | $23.4M | Reduce -60.0% |
| CGON CG Oncology Inc. | 5.12% | 579,895 | $23.4M | Reduce -1.1% |
| IRON Disc Medicine Inc. | 4.94% | 340,897 | $22.5M | Reduce -13.9% |
| PHVS Pharvaris NV | 4.85% | 886,332 | $22.1M | New |
| XENE Xenon Pharmaceuticals Inc. | 4.44% | 503,701 | $20.2M | Add +7.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.91% | 734,539 | $17.8M | Reduce -7.4% |
| MRUS Merus NV | 3.80% | 184,135 | $17.3M | Reduce -17.9% |
| LENZ Lenz Therapeutics Inc. | 3.76% | 368,176 | $17.1M | Add +7.6% |
| OCUL Ocular Therapeutix Inc. | 2.95% | 1,151,686 | $13.5M | Add +58.1% |
| MNPR Monopar Therapeutics Inc. | 2.78% | 155,370 | $12.7M | New |
| NAMS Newamsterdam Pharma Co. NV | 0.96% | 153,147 | $4.4M | Reduce -30.6% |
Portfolio Sells Q2 2025 → Q3 2025
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −5.56 |
| IRON Disc Medicine Inc. | Reduce -13.9% | 4.94% | −3.56 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −2.96 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −2.67 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −2.30 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −1.90 |
| CELC Celcuity Inc. | Reduce -60.0% | 5.13% | −1.28 |
| CGON CG Oncology Inc. | Reduce -1.1% | 5.12% | −1.06 |
| MRUS Merus NV | Reduce -17.9% | 3.80% | −0.98 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -30.6% | 0.96% | −0.66 |
| CTNM Contineum Therapeutics Inc. Class A | Sold out | 0.00% | −0.51 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.49 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -7.4% | 3.91% | −0.32 |
| COGT Cogent Biosciences Inc. | Reduce -11.9% | 6.38% | −0.31 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.29 |
| SLN Silence Therapeutics PLC-ADR | Sold out | 0.00% | −0.08 |
Portfolio Buys Q2 2025 → Q3 2025
| ABVX Abivax SA-ADR | Add +28.7% | 14.92% | +12.99 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +41.2% | 13.72% | +5.25 |
| PHVS Pharvaris NV | New | 4.85% | +4.85 |
| MNPR Monopar Therapeutics Inc. | New | 2.78% | +2.78 |
| DYN Dyne Therapeutics Inc. | Add +83.8% | 7.42% | +1.80 |
| OCUL Ocular Therapeutix Inc. | Add +58.1% | 2.95% | +0.21 |
| JAZZ Jazz Pharmaceuticals PLC | Add +45.3% | 8.69% | −0.21 |
| LENZ Lenz Therapeutics Inc. | Add +7.6% | 3.76% | −0.30 |
| PCVX Vaxcyte Inc. | Add +44.9% | 6.23% | −0.94 |
| XENE Xenon Pharmaceuticals Inc. | Add +7.5% | 4.44% | −1.51 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |